Products

Get a quote

We're excited to learn more about your project and provide you with a customized quote tailored to your needs. Please fill out the form below, and we'll get back to you as soon as possible.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mouse Anti‑Herpes Simplex Virus Type 1&2 Glycoprotein B Monoclonal Antibody

Product Overview

BioVenic mouse monoclonal antibody is specific for herpes simplex virus type 1 and 2 glycoprotein B. It is affinity purified from protein A. It can be applied to ELISA and ICC assays of herpes simplex virus type 1 and 2 glycoprotein B.

Specifications

Application ICC; ELISA

Clonality Monoclonal

Classification Primary Antibody

Clone L8N7

Host Mouse

Target Species Virus

Species Reactivity Virus

Specificity Herpes Simplex Virus Type 1 and 2 Glycoprotein B

Isotype IgG2

Immunogen Recombinant herpes simplex virus glycoprotein B

Purification Protein A Purified

Purity ≥ 95% (SDS-PAGE)

Conjugation Unconjugated

Preservative and Stabilizer 15mM Sodium Azide

Buffer Phosphate Buffered Saline, pH 7.4

Physical State Liquid

Target Information

Glycoprotein B (gB) of both Herpes Simplex Virus Type 1 (HSV-1) and Type 2 (HSV-2) is a key component of the viral envelope, essential for viral entry into host cells. It mediates membrane fusion and is a major antigen for the host immune response. gB is a promising target for vaccine development due to its role in the early stages of infection and its ability to elicit neutralizing antibodies.

Target Herpes Simplex Virus Type 1 and 2 Glycoprotein B

Target Synonym gB

Taxonomy ID 104388

Shipping and Storage

This product is shipped with ice gel packs. Store at 2°C - 8°C (up to 12 months) on receipt. Avoid repeated freezing and thawing as this may denature the antibody.

Documents

Datasheet

COA

To request a Certificate of Analysis, please enter the Lot No. in the search box. Note: Certificate of Analysis not available for kits.

The product is for research use only.
Not for commercial, prophylactic, diagnostic, or therapeutic applications.

References

Silke Heilingloh, Christiane, et al. "Herpes simplex virus type 2 is more difficult to neutralize by antibodies than herpes simplex virus type 1." Vaccines 8.3 (2020): 478.